Chengdu Bright Eye Hospital Group Future Growth
Future criteria checks 4/6
Chengdu Bright Eye Hospital Group is forecast to grow earnings and revenue by 53.8% and 18.6% per annum respectively. EPS is expected to grow by 53.7% per annum. Return on equity is forecast to be 8.6% in 3 years.
Key information
53.8%
Earnings growth rate
53.7%
EPS growth rate
| Healthcare earnings growth | 22.4% |
| Revenue growth rate | 18.6% |
| Future return on equity | 8.6% |
| Analyst coverage | Low |
| Last updated | 10 May 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4,173 | 333 | N/A | 728 | 1 |
| 12/31/2025 | 4,044 | 356 | N/A | 686 | 2 |
| 12/31/2024 | 3,044 | 160 | N/A | 166 | 1 |
| 6/30/2024 | 2,760 | 76 | -125 | 542 | N/A |
| 3/31/2024 | 2,744 | 122 | 5 | 620 | N/A |
| 12/31/2023 | 2,718 | 268 | -12 | 614 | N/A |
| 9/30/2023 | 2,459 | 244 | 30 | 605 | N/A |
| 6/30/2023 | 2,214 | 204 | -111 | 475 | N/A |
| 3/31/2023 | 1,907 | 146 | -153 | 317 | N/A |
| 1/1/2023 | 1,726 | 21 | -9 | 319 | N/A |
| 9/30/2022 | 1,785 | 70 | 28 | 342 | N/A |
| 6/30/2022 | 1,753 | 80 | 88 | 340 | N/A |
| 3/31/2022 | 1,755 | 99 | 103 | 376 | N/A |
| 1/1/2022 | 1,710 | 94 | 105 | 359 | N/A |
| 12/31/2020 | 1,362 | 109 | 81 | 228 | N/A |
| 12/31/2019 | 1,193 | 49 | -141 | 105 | N/A |
| 12/31/2018 | 1,016 | 31 | 5 | 88 | N/A |
| 12/31/2017 | 806 | -13 | N/A | 27 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 301239's forecast earnings growth (53.8% per year) is above the savings rate (2.9%).
Earnings vs Market: 301239's earnings (53.8% per year) are forecast to grow faster than the CN market (21.9% per year).
High Growth Earnings: 301239's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 301239's revenue (18.6% per year) is forecast to grow faster than the CN market (13.4% per year).
High Growth Revenue: 301239's revenue (18.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 301239's Return on Equity is forecast to be low in 3 years time (8.6%).